Therefore, increased dosing is required to achieve concentrations sufficient to effectively suppress PI3K-signaling in brain tumors, to promote PI3K-inhibitor–related side effects (rash, mucositis, neutropenia, and hyperglycemia), which reduces patient compliance (29). Here, PIK3CA is linked to neutropenia.